Filing Flows › Abbott Laboratories (ABT) › Capital expenditures
Abbott Laboratories (ABT) capital expenditures by quarter
Abbott Laboratories' capital expenditures were $513M in Q3 2026 (third quarter 2026), +3% from Q2 2026. Over the last 7 quarters it ranged from $399M (Q1 2026) to $689M (Q4 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $513M | +3% | +3% |
| Q2 2026 | $497M | +25% | -1% |
| Q1 2026 | $399M | -42% | -18% |
| Q4 2025 | $689M | +39% | — |
| Q3 2025 | $496M | -1% | — |
| Q2 2025 | $502M | +4% | — |
| Q1 2025 | $484M | — | — |
Q3 2026 at a glance
Abbott Laboratories, Q3 2026: revenue $13.0B (+14% year over year), operating margin 10.4%, net earnings $920M, operating cash flow $1.7B. The chart follows the revenue to costs, profit and cash.
Questions
What is Abbott Laboratories' capital expenditures?
Abbott Laboratories' capital expenditures were $513M in Q3 2026 (third quarter 2026), +3% from Q2 2026.
How has Abbott Laboratories' capital expenditures changed?
Over the last 7 quarters it ranged from $399M (Q1 2026) to $689M (Q4 2025).